


CLAIMS

What is claimed is:

1. A compound of Formula (I), (II) or (III), or a pharmaceutically acceptable salt thereof,

wherein the compound of Formula (I) is:



(I)

wherein:

X₃ is:

(1) 	(2)
(3) 	(4)
(5) 	(6) -N(D ₁)-S(O) ₂ -CF ₃ ;

(7) -N(D₁)-C(O)-N(D₁)-CH₂-CH₂-CH₃;

(8) -C(O)-U₃D₁;

(9) -C(O)-CH₂-NH(D₁);

(10) $-\text{S}(\text{O})_2-\text{N}(\text{D}_1)-\text{C}(\text{O})-\text{C}_6\text{H}_5$;

(11) $-\text{S}(\text{O})_2-\text{N}(\text{D}_1)-\text{C}(\text{O})-\text{ND}_1-\text{CH}_2-\text{CH}_2-\text{CH}_3$; or

(12) $-\text{S}(\text{O})_2-\text{N}(\text{D}_1)-\text{OD}_1$;









D_4 is D_1 , $-\text{C}(\text{O})-\text{CH}_2-\text{NH}(\text{D}_1)$ or $-\text{C}(\text{C}_6\text{H}_5)_3$;


Z_3 is a carbon, $-\text{CH}$ or a nitrogen atom;











R_{10} is a fluorine or a hydrogen atom;


Y_3 is:

5

<p>(1)</p> 	<p>(2)</p> 
<p>(3)</p> 	<p>(4)</p> 
<p>(5)</p> 	<p>(6)</p> 
<p>(7)</p> 	<p>(8)</p> 



<p>(19)</p> 	<p>(20)</p> 
<p>(21)</p> 	<p>(22)</p> 
<p>(23)</p> 	<p>(24)</p> 
<p>(25)</p> 	<p>(26)</p> 
<p>(27)</p> 	<p>(28)</p>  <p>or</p>



Z_4 is C- R_{29} or a nitrogen;

R_{11} is:

- (1) $-\text{CH}_2-\text{OD}_1$;
- (2) $-\text{C}(\text{O})-\text{U}_3\text{D}_1$;
- (3) $-\text{C}(\text{O})-\text{O}-\text{CH}(\text{CH}_3)-\text{O}-\text{C}(\text{O})-\text{OR}_{13}$; or
- (4) $-\text{CH}_2-\text{N}(\text{D}_1)-\text{C}(\text{O})-\text{OR}_{13}$;


R_{12} is a chlorine, $-\text{SCH}_3$ or a haloalkyl;

R_{13} is a lower alkyl or K;


R_{14} is a lower alkyl or a cycloalkyl;

R_{15} is:

- (1) hydrogen;
- (2) a lower alkyl;
- (3)



(4)



or

- (5) $-\text{C}(\text{O})-\text{U}_3\text{D}_1$;

R_{16} is a hydrogen, a lower alkyl, an alkoxy, $-\text{OD}_1$, a cyano, $-\text{C}(\text{O})-\text{U}_3\text{D}_1$,

$\text{NH}(\text{D}_1)$ or an alkylcarbonyl;


R_{17} is an aryl or a cycloalkyl;

R_{18} at each occurrence is independently selected from a lower alkyl, an alkoxyalkyl, an alkylcarboxylic acid, an hydroxyalkyl, an arylalkoxy, an arylalkyl or an aryl;


R_{19} is a hydrogen or $-C(O)-U_3D_1$;

5 R_{20} is a hydrogen, a lower alkyl or $-C(O)-U_3D_1$;

R_{21} is:




R_{22} is a hydrogen, $-C(O)-U_3D_1$ or



10 R_{23} is a lower alkyl or an alkoxyalkyl;

R_{24} is a hydrogen, an alkyl or an aryl;

R_{25} is $-(CH_2)_2-OD_1$ or



R_{26} is a hydrogen, a lower alkyl, a lower haloalkyl, an aryl or an arylalkyl;

15 R_{27} is a lower alkyl, an aryl an arylalkyl or $-(CH_2)_k-C(O)U_3D_1$;


R_{28} is $-OD_1$, $-S(O)_2-N(D_1)H$, $-N(D_1)H$, $-C(O)-U_3D_1$ or CH_2-OD_1 ;

R_{29} is a hydrogen, a lower alkyl or $-C(O)U_3D_1$;

R_{30} is a lower alkyl or a haloalkyl;

R_{31} is:

20



o_1 is an integer from 0 to 3;

k is an integer from 1 to 3;

D_1 is a hydrogen, V_3 or K ;

5 K is $-(W_3)_a-E_b-(C(R_e)(R_f))_{p_1}-E_c-(C(R_e)(R_f))_x-(W_3)_d-(C(R_e)(R_f))_y-(W_3)_i-E_j-(W_3)_g-(C(R_e)(R_f))_z-U_3-V_3$;

V_3 is $-\text{NO}$ or $-\text{NO}_2$;

a, b, c, d, g, i and j are each independently an integer from 0 to 3;

p_1, x, y and z are each independently an integer from 0 to 10;

10 W_3 at each occurrence is independently $-\text{C}(\text{O})-$, $-\text{C}(\text{S})-$, $-\text{T}_3-$, $-(\text{C}(\text{R}_e)(\text{R}_f))_h-$, an alkyl group, an aryl group, a heterocyclic ring, an arylheterocyclic ring, or $-(\text{CH}_2\text{CH}_2\text{O})_{q_1}-$;

E at each occurrence is independently $-\text{T}_3-$, an alkyl group, an aryl group, $-(\text{C}(\text{R}_e)(\text{R}_f))_h-$, a heterocyclic ring, an arylheterocyclic ring, or $-(\text{CH}_2\text{CH}_2\text{O})_{q_1}-$;

15 T_3 at each occurrence is independently a covalent bond, a carbonyl, an oxygen, $-\text{S}(\text{O})_{o-}$ or $-\text{N}(\text{R}_a)\text{R}_i$;

h is an integer from 1 to 10;

q_1 is an integer from 1 to 5;

20 R_e and R_f are each independently a hydrogen, an alkyl, a cycloalkoxy, a halogen, a hydroxy, an hydroxyalkyl, an alkoxyalkyl, an arylheterocyclic ring, an alkylaryl, an alkylcycloalkyl, an alkylheterocyclic ring, a cycloalkylalkyl, a cycloalkylthio, an arylalkylthio, an arylalkylthioalkyl, an alkylthioalkyl, a cycloalkenyl, an heterocyclicalkyl, an alkoxy, a haloalkoxy, an amino, an alkylamino, a dialkylamino, an arylamino, a diarylamino, an alkylaryl amino, an alkoxyhaloalkyl, a sulfonic acid, a
25 sulfonic ester, an alkylsulfonic acid, an arylsulfonic acid, an arylalkoxy, an alkylthio, an arylthio, a cyano, an aminoalkyl, an aminoaryl, an aryl, an arylalkyl, an alkylaryl, a

carboxamido, an alkylcarboxamido, an arylcarboxamido, an amidyl, a carboxyl, a carbamoyl, an alkylcarboxylic acid, an arylcarboxylic acid, an alkylcarbonyl, an arylcarbonyl, an ester, a carboxylic ester, an alkylcarboxylic ester, an arylcarboxylic ester, a sulfonamido, an alkylsulfonamido, an arylsulfonamido, an alkylsulfonyl, an alkylsulfonyloxy, an arylsulfonyl, arylsulphonyloxy, a sulfonic ester, an alkyl ester, an aryl ester, a urea, a phosphoryl, a nitro, K or R_e and R_f taken together with the carbons to which they are attached form a carbonyl, a methanthial, a heterocyclic ring, a cycloalkyl group, an aryl group, an oxime, a hydrazone or a bridged cycloalkyl group;

U₃ at each occurrence is independently an oxygen, -S(O)_o- or -N(R_a)R_i;


o is an integer from 0 to 2;

R_a is a lone pair of electrons, a hydrogen or an alkyl group;

R_i is a hydrogen, an alkyl, an aryl, an alkylcarboxylic acid, an arylcarboxylic acid, an alkylcarboxylic ester, an arylcarboxylic ester, an alkylcarboxamido, an arylcarboxamido, an alkylaryl, an alkylsulfinyl, an alkylsulfonyl, an alkylsulfonyloxy, an arylsulfinyl, an arylsulfonyl, arylsulphonyloxy, a sulfonamido, a carboxamido, a carboxylic ester, an aminoalkyl, an aminoaryl, -CH₂-C(U₃-V₃)(R_e)(R_f), a bond to an adjacent atom creating a double bond to that atom, -(N₂O₂)⁻•M₁⁺, wherein M₁⁺ is an organic or inorganic cation; and

with the proviso that the compounds of Formula (I) must contain at least one NO group, and/or at least one NO₂ group; wherein the at least one NO group and/or the at least one NO₂ group is linked to the compound through an oxygen atom, a nitrogen atom or a sulfur atom; and

the compound of Formula (II) is:



(II)


wherein:

U₃ and D₁ are as defined herein; and

5 with the proviso that the compounds of Formula (II) must contain at least one NO group, and/or at least one NO₂ group; wherein the at least one NO group and/or the at least one NO₂ group is linked to the compound through an oxygen atom, a nitrogen atom or a sulfur atom; and

the compound of Formula (III) is:

10



(III)

wherein:

X₃ and Y₃ are as defined herein; and

15 with the proviso that the compounds of Formula (III) must contain at least one NO group, and/or at least one NO₂ group; wherein the at least one NO group and/or the at least one NO₂ group is linked to the compounds through an oxygen atom, a nitrogen atom or a sulfur atom.

2. A composition comprising the compound of claim 1 and a

pharmaceutically acceptable carrier.


3. The compound of claim 1, wherein the compound of Formula (I) is a nitrosated abitesartan, a nitrosylated abitesartan, a nitrosated and nitrosylated abitesartan, a nitrosated candesartan, a nitrosylated candesartan, a nitrosated and nitrosylated candesartan, a nitrosated elisartan, a nitrosylated elisartan, a nitrosated and nitrosylated elisartan, a nitrosated embusartan, a nitrosylated embusartan, a nitrosated and nitrosylated embusartan, a nitrosated enoltasartan, a nitrosylated enoltasartan, a nitrosated and nitrosylated enoltasartan, a nitrosated fonsartan, a nitrosylated fonsartan, a nitrosated and nitrosylated fonsartan, a nitrosated forasartan, a nitrosylated forasartan, a nitrosated and nitrosylated forasartan, a nitrosated glycylosartan, a nitrosylated glycylosartan, a nitrosated and nitrosylated glycylosartan, a nitrosated irbesartan, a nitrosylated irbesartan, a nitrosated and nitrosylated irbesartan, a nitrosated losartan, a nitrosylated losartan, a nitrosated and nitrosylated losartan, a nitrosated olmesartan, a nitrosylated olmesartan, a nitrosated and nitrosylated olmesartan, a nitrosated milfasartan, a nitrosylated milfasartan, a nitrosated and nitrosylated milfasartan, a nitrosated ripisartan, a nitrosylated ripisartan, a nitrosated and nitrosylated ripisartan, a nitrosated tasosartan, a nitrosylated tasosartan, a nitrosated and nitrosylated tasosartan, a nitrosated telmisartan, a nitrosylated telmisartan, a nitrosated and nitrosylated telmisartan, a nitrosated valsartan, a nitrosylated valsartan, a nitrosated and nitrosylated valsartan, a nitrosated SR-47436, a nitrosylated SR-47436, a nitrosated and nitrosylated SR-47436, or a nitrosated, or a nitrosylated, or a nitrosated and nitrosylated compound of any of the following compounds of ACS registry number 124750-92-1, 133240-46-7, 135070-05-2, 139958-16-0, 145160-84-5, 147403-03-0, 153806-29-2, 439904-54-8P, 439904-55-9P, 439904-56-0P, 439904-57-1P, 439904-58-2P, 155918-60-8P, 155918-61-9P, 272438-16-1P, 272446-75-0P, 223926-77-0P, 169281-89-4, 439904-65-1P, 165113-01-9P, 165113-02-0P, 165113-03-1P, 165113-03-2P, 165113-05-3P, 165113-06-4P, 165113-07-5P, 165113-08-6P, 165113-09-7P, 165113-10-0P, 165113-11-1P, 165113-12-2P, 165113-17-7P, 165113-18-8P, 165113-19-9P, 165113-20-2P, 165113-13-3P, 165113-14-4P, 165113-15-5P, 165113-16-6P, 165113-21-3P, 165113-22-4P, 165113-23-5P, 165113-24-6P, 165113-25-7P, 165113-26-8P, 165113-27-9P, 165113-28-0P, 165113-29-1P, 165113-30-4P, 165113-31-5P,

165113-32-6P, 165113-33-7P, 165113-34-8P, 165113-35-9P, 165113-36-0P, 165113-37-1P, 165113-38-2P, 165113-39-3P, 165113-40-6P, 165113-41-7P, 165113-42-8P, 165113-43-9P, 165113-44-0P, 165113-45-1P, 165113-46-2P, 165113-47-3P, 165113-48-4P, 165113-49-5P, 165113-50-8P, 165113-51-9P, 165113-52-0P, 165113-53-1P, 165113-54-2P, 165113-55-3P, 165113-56-4P, 165113-57-5P, 165113-58-6P, 165113-59-7P, 165113-60-0P, 165113-61-1P, 165113-62-2P, 165113-63-3P, 165113-64-4P, 165113-65-5P, 165113-66-6P, 165113-67-7P, 165113-68-8P, 165113-69-9P, 165113-70-2P, 165113-71-3P, 165113-72-4P, 165113-73-5P, 165113-74-6P, 114798-27-5, 114798-28-6, 114798-29-7, 124749-82-2, 114798-28-6, 124749-84-4, 124750-88-5, 124750-91-0, 124750-93-2, 161946-65-2P, 161947-47-3P, 161947-48-4P, 161947-51-9P, 161947-52-0P, 161947-55-3P, 161947-56-4P, 161947-60-0P, 161947-61-1P, 161947-68-8P, 161947-69-9P, 161947-70-2P, 161947-71-3P, 161947-72-4P, 161947-74-6P, 161947-75-7P, 161947-81-5P, 161947-82-6P, 161947-83-7P, 161947-84-8P, 161947-85-9P, 161947-86-0P, 161947-87-1P, 161947-88-2P, 161947-89-3P, 161947-90-6P, 161947-91-7P, 161947-92-8P, 161947-93-9P, 161947-94-0P, 161947-95-1P, 161947-96-2P, 161947-97-3P, 161947-98-4P, 161947-99-5P, 161948-00-1P, 161948-01-2P, 161948-02-3P, 168686-32-6P, 167301-42-0P, 166813-82-7P, 166961-56-4P, 166961-58-6P, 158872-96-9P, 158872-97-0P, 158807-14-8P, 158807-15-9P, 158807-16-0P, 158807-17-1P, 158807-18-2P, 158807-19-3P, 158807-20-6P, 155884-08-5P, 154749-99-2, 167371-59-7P, 244126-99-6P, 177848-35-0P and 141309-82-2P; the compound of Formula (II) is a nitrosated eprosartan, a nitrosylated eprosartan, a nitrosated and nitrosylated eprosartan; the compound of Formula (III) is a nitrosated saprisartan, a nitrosylated saprisartan, a nitrosated and nitrosylated saprisartan, a nitrosated zalasartan, a nitrosylated zalasartan, a nitrosated and nitrosylated zalasartan, or pharmaceutically acceptable salts thereof.

4. The compound of claim 1, wherein K is:


(1) $-Y-(CR_4R'_4)_p-T-(CR_4R'_4)_p-ONO_2$;

(2)



wherein T is ortho, meta or para;

(3)



(4) $\text{---Y---(CR}_4\text{R}'_4)_p\text{---V---B---T---(CR}_4\text{R}'_4)_p\text{---ONO}_2$;

(5) $\text{---Y---(CR}_4\text{R}'_4)_p\text{---T---C(O)---(CR}_4\text{R}'_4)_o\text{---(CH}_2\text{)---ONO}_2$;

(6) $\text{---Y---(CR}_4\text{R}'_4)_p\text{---C(Z)---(CH}_2\text{)}_q\text{---T---(CR}_4\text{R}'_4)_q\text{---(CH}_2\text{)---ONO}_2$;

(7) $\text{---Y---(CR}_4\text{R}'_4)_p\text{---T---(CH}_2\text{)}_q\text{---V---(CR}_4\text{R}'_4)_q\text{---(CH}_2\text{)---ONO}_2$;

(8) $\text{---Y---(CR}_4\text{R}'_4)_p\text{---V---(CH}_2\text{)}_q\text{---V---(CR}_4\text{R}'_4)_q\text{---(CH}_2\text{)---ONO}_2$;

(9) $\text{---Y---(CR}_4\text{R}'_4)_o\text{---(W)}_q\text{---(CR}_4\text{R}'_4)_o\text{---(CH}_2\text{)---ONO}_2$;

(10) $\text{---NR}_j\text{---O---(CH}_2\text{)}_o\text{---V---(CR}_4\text{R}'_4)_q\text{---(CH}_2\text{)---ONO}_2$;

(11) $\text{---NR}_j\text{---O---(CH}_2\text{)}_o\text{---(W)}_q\text{---(CR}_4\text{R}'_4)_q\text{---(CH}_2\text{)---ONO}_2$;

(12) $\text{---O---NR}_j\text{---(CH}_2\text{)}_o\text{---(W)}_q\text{---(CR}_4\text{R}'_4)_q\text{---(CH}_2\text{)---ONO}_2$;

(13) $\text{---Y---(CH}_2\text{)}_o\text{---(W)}_q\text{---(CH}_2\text{)}_o\text{---V---(CR}_4\text{R}'_4)_o\text{---Q'---(CR}_4\text{R}'_4)_o\text{---(CH}_2\text{)---ONO}_2$;

(14) $\text{---Y---(CR}_4\text{R}'_4)_p\text{---V---(CH}_2\text{)}_o\text{---(W)}_q\text{---(CR}_4\text{R}'_4)_q\text{---(CH}_2\text{)---ONO}_2$;

(15) $\text{---O---NR}_j\text{---(CH}_2\text{)}_o\text{---V---(CR}_4\text{R}'_4)_q\text{---(CH}_2\text{)---ONO}_2$;

(16) $\text{---Y---(CR}_4\text{R}'_4)_o\text{---Q'---(CR}_4\text{R}'_4)_o\text{---V---(CR}_4\text{R}'_4)_o\text{---(CH}_2\text{)---ONO}_2$;

(17) $\text{---Y---(CR}_4\text{R}'_4)_o\text{---Q'---(CR}_4\text{R}'_4)_o\text{---(W)}_q\text{---(CR}_4\text{R}'_4)_o\text{---(CH}_2\text{)---ONO}_2$;

(18) $\text{---Y---(CR}_4\text{R}'_4)_p\text{---T---(CR}_4\text{R}'_4)_p\text{---Q'---(CR}_4\text{R}'_4)_o\text{---(CH}_2\text{)---ONO}_2$;

(19) $\text{---Y---(CR}_4\text{R}'_4)_q\text{---C(Z)---(CR}_4\text{R}'_4)_o\text{---(CH}_2\text{)---ONO}_2$;

(20) $\text{---Y---(CR}_4\text{R}'_4)_p\text{---Q'---(CR}_4\text{R}'_4)_o\text{---(CH}_2\text{)---ONO}_2$;

(21) $\text{---Y---(CR}_4\text{R}'_4)_q\text{---P(O)MM'}$;

(22) $\text{---Y---(CR}_4\text{R}'_4)_o\text{---Q'---(CR}_4\text{R}'_4)_o\text{---(CH}_2\text{)---ONO}_2$;

(23) $\text{---Y---(CR}_4\text{R}'_4)_o\text{---Q'---(CR}_4\text{R}'_4)_o\text{---T---(CR}_4\text{R}'_4)_o\text{---(CH}_2\text{)---ONO}_2$;

(24) $\text{---Y---(CR}_4\text{R}'_4)_q\text{---(W)}_q\text{---(CR}_4\text{R}'_4)_o\text{---Q'---(CR}_4\text{R}'_4)_o\text{---(CH}_2\text{)---ONO}_2$;

(25) $\text{---Y---(CR}_4\text{R}'_4)_q\text{---V---(CR}_4\text{R}'_4)_o\text{---Q'---(CR}_4\text{R}'_4)_o\text{---(CH}_2\text{)---ONO}_2$;

(26) $\text{---Y---(CR}_4\text{R}'_4)_p\text{---(T)}_o\text{---(W)}_q\text{---(CR}_4\text{R}'_4)_o\text{---(CH}_2\text{)---ONO}_2$;

(27) $\text{---Y---(CR}_4\text{R}'_4)_p\text{---(W)}_q\text{---(T)}_o\text{---(CR}_4\text{R}'_4)_o\text{---(CH}_2\text{)---ONO}_2$;

(28) $\text{---Y---(CR}_4\text{R}'_4)_q\text{---C(Z)---V---(CR}_4\text{R}'_4)_q\text{---(CH}_2\text{)---ONO}_2$;

(29) $\text{---Y---(CR}_4\text{R}'_4)_o\text{---C(R}_4\text{)(ONO}_2\text{)---(CR}_4\text{R}'_4)_q\text{---(T)}_o\text{---(W)}_q\text{---(T)}_o\text{---(CR}_4\text{R}'_4)_o\text{---R}_5$;

(30) $-Y-(CR_4R_4')_o-V-(CR_4R_4')_o-Q'-(CR_4R_4')_o-(CH_2)-ONO_2$;

(31) $-Y-(CR_4R_4')_q-C(Z)-Q'-(CR_4R_4')_o-(CH_2)-ONO_2$;

(32) $-Y-(CR_4R_4')_p-V-(CR_4R_4')_p-(CH_2)-ONO_2$;

(33) $-Y-(CR_4R_4')_p-V-(CH_2)_q-(T)_o-(CR_4R_4')_q-(CH_2)-ONO_2$;

5 (34) $-Y-(CR_4R_4')_p-(T)_o-Q'-(T)_o-(CR_4R_4')_q-(CH_2)-ONO_2$;

(35) $-Y-(CR_4R_4')_q-C(Z)-(CR_4R_4')_q-V-(CR_4R_4')_o-Q'-(CR_4R_4')_o-(CH_2)-ONO_2$;

(36) $-Y-(CR_4R_4')_q-C(Z)-(CR_4R_4')_q-(W)_q-(CR_4R_4')_o-Q'-(CR_4R_4')_o-(CH_2)-ONO_2$;

(37) $-NR_j-O-(CH_2)_o-V-(CR_4R_4')_o-Q'-(CH_2)-ONO_2$;

10 (38) $-NR_j-O-(CH_2)_o-(W)_q-(CR_4R_4')_o-Q'-(CH_2)-ONO_2$;

(39) $-O-NR_j-(CH_2)_o-(W)_q-(CR_4R_4')_o-Q'-(CH_2)-ONO_2$;

(40) $-O-NR_j-(CH_2)_o-V-(CR_4R_4')_o-Q'-(CH_2)-ONO_2$;

(41) $-NR_j-NR_j-(CR_4R_4')_p-(W)_q-(T)_o-(CR_4R_4')_o-(CH_2)-ONO_2$; or

(42) $-Y-(CR_4R_4')_o-Q'-(CR_4R_4')_o-ONO_2$; or

15 (43) $-Y-(CR_4R_4')_o-V-(CR_4R_4')_o-Q-(CR_4R_4')_o-ONO_2$;

R_4 and R_4' at each occurrence are independently a hydrogen, lower alkyl group, -OH, -CH₂OH, -ONO₂, -NO₂ or -CH₂ONO₂; or R_4 and R_4' taken together with the carbon atom to which they are attached are a cycloalkyl group or a heterocyclic ring;

V is -C(O)-T-, -T-C(O)-, -T-C(O)-T or T-C(O)-C(O)-T;

20 W is a covalent bond or a carbonyl group;

T at each occurrence is independently an oxygen, (S(O)_o)_o or NR_j;

R_j is a hydrogen, an alkyl group, an aryl group, a heterocyclic ring, an alkylcarbonyl group, an alkylaryl group, an alkylsulfinyl group, an alkylsulfonyl group, an arylsulfinyl group, an arylsulfonyl group, a sulfonamido group, a N-alkylsulfonamido group, a N,N-diarylsulfonamido group, a N-arylsulfonamido group, a N-alkyl-N-arylsulfonamido group, a carboxamido group or a hydroxyl group;

p at each occurrence is independently an integer from 1 to 6;

q at each occurrence is independently an integer from 1 to 3;

o at each occurrence is independently an integer from 0 to 2;

30 Y is independently a covalent bond, a carbonyl, an oxygen, -S(O)_o- or -NR_j;

B is either phenyl or (CH₂)_o;













Q' is a cycloalkyl group, a heterocyclic ring or an aryl group;

Z is (=O), (=N-OR₅), (=N-NR₅R'₅) or (=CR₅R'₅);


M and M' are each independently -O⁻ H₃N⁺-(CR₄R'₄)_q-CH₂ONO₂ or
-T-(CR₄R'₄)_o-CH₂ONO₂; and

- 5 R₅ and R'₅ at each occurrence are independently a hydrogen, a hydroxyl group, an alkyl group, an aryl group, an alkylsulfonyl group, an arylsulfonyl group, a carboxylic ester, an alkylcarbonyl group, an arylcarbonyl group, a carboxamido group, an alkoxyalkyl group, an alkoxyaryl group, a cycloalkyl group or a heterocyclic ring.

5. The compound of claim 1, wherein K is:




(13)




wherein T' maybe ortho, meta or para


(15)




(17)




(19)




(21)




(23)




(14)




(16)




(18)




(20)




(22)




(24)




(25)




(26)




(27)




(28)




(29)




(30)




(31)




(32)




(33)




(34)




(35)




(36)




(37)




(38)




(39)




(40)




(41)




(42)




(43)




(44)




(45)




(46)




(47)




(48)




(49)




(50)




(51)




(52)




(53)




(54)



(55)



(56)



wherein:

Y' a covalent bond, a carbonyl, an oxygen, -S(O)_o- or -NR₆;

T' is oxygen, sulfur or NR₆;

X₅ is oxygen, (S(O)_o)_o or NR₆;

R₆ is a hydrogen, a lower alkyl group, an aryl group;

5 R₇ is a lower alkyl group or an aryl group;


R₈ at each occurrence is independently is a hydrogen, a hydroxyl group, a lower alkyl group, an aryl group, -NO₂, -CH₂-ONO₂ or -CH₂-OH;

n' and m' are each independently an integer from 0 to 10; and


o is an integer from 0 to 2.

10 6. The compound of claim 1, wherein the compound of Formula (I) is compound of Formula (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII), (XIV), (XV), (XVI), (XVII), (XVIII) or (XIX); the compound of Formula (II) is a compound of Formula (XX); and the compound of Formula (III) is a compound of Formula (XXI) or (XXII); or a pharmaceutically acceptable salt thereof,


15 wherein the compound of Formula (IV) is:



and the compound of Formula (V) is:




and the compound of Formula (VI) is:




(VI)

and the compound of Formula (VII) is:




(VII)

and the compound of Formula (VIII) is:




(VIII)

and the compound of Formula (IX) is:




and the compound of Formula (X) is:




5

and the compound of Formula (XI) is:




10

and the compound of Formula (XII) is:




(XII)

and the compound of Formula (XIII) is:




(XIII)

and the compound of Formula (XIV) is:



(XIV)


and the compound of Formula (XV) is:



(XV)


5

and the compound of Formula (XVI) is:



(XVI)


and the compound of Formula (XVII) is:



(XVII)


10

and the compound of Formula (XVIII) is:




(XVIII)

and the compound of Formula (XIX) is:




(XIX)

and the compound of Formula (XX) is:




(XX)

and the compound of Formula (XXI) is:



(XXI)

and the compound of Formula (XXII) is:



(XXII)

wherein

T' is oxygen, sulfur or NR₆;

nBu is the lower alkyl group CH₃-CH₂-CH₂-CH₂-;

nPr is the lower alkyl group CH₃-CH₂-CH₂-;

iPr is the lower alkyl group (CH₃)₂-CH-;

OEt is the alkoxy group -OCH₂-CH₃;


R₆ is a hydrogen, a lower alkyl group, an aryl group;

R_m-R_n taken together can be a hydrogen atom; or


R_n is:


a hydrogen or


(1)




(2)









wherein:

R_9 is a lower alkyl group;

T' is oxygen, sulfur or NR_6 ;

R_6 is a hydrogen, a lower alkyl group, an aryl group; and

with the proviso that the compounds of Formula (IV) to Formula (XXII) must contain at least one $-NO_2$ group.

7. A method for treating a cardiovascular disease in a patient in need thereof comprising administering to the patient a therapeutically effective amount of the composition of claim 2.

8. The method of claim 7, wherein the cardiovascular disease is congestive heart failure, restenosis, hypertension, diastolic dysfunction, a coronary artery disease, myocardial infarction, cerebral infarction, atherosclerosis, atherogenesis, cerebrovascular disease, angina, aneurysm, ischemic heart disease, cerebral ischemia, myocardial ischemia, thrombosis, platelet aggregation, platelet adhesion, smooth muscle cell proliferation, a vascular or non-vascular complication associated with the use of a medical device, a wound associated with the use of a medical device, vascular or non-vascular wall damage, peripheral vascular disease, neointimal hyperplasia following percutaneous transluminal coronary angiograph, vascular grafting, coronary artery bypass surgery, a thromboembolic event, post-angioplasty restenosis, coronary plaque inflammation, hypercholesterolemia, embolism, stroke, shock, arrhythmia, atrial

fibrillation or atrial flutter, or thrombotic occlusion and reclusion cerebrovascular incident.

9. The method of claim 8, wherein the cardiovascular disease is congestive heart failure, hypertension or diastolic dysfunction.

5 10. A method for treating a renovascular disease in a patient in need thereof comprising administering to the patient a therapeutically effective amount of the composition of claim 2.

11. The method of claim 10, wherein the renovascular disease is renal failure or renal insufficiency.

10 12. A method for treating a disease resulting from oxidative stress; treating an endothelial dysfunction; treating a disease caused by endothelial dysfunction; treating cirrhosis; treating pre-eclampsia; treating osteoporosis; or treating nephropathy in a patient in need thereof comprising administering to the patient a therapeutically effective amount of the composition of claim 2.

15 13. The composition of claim 2, further comprising (i) at least one therapeutic agent; (ii) at least one nitric oxide donor compound; or (iii) at least one therapeutic agent and at least one nitric oxide donor compound.

20 14. The composition of claim 13, wherein the therapeutic agent is an aldosterone antagonist, an alpha-adrenergic receptor antagonist, an angiotensin II antagonist, an angiotensin-converting enzyme inhibitor, an antidiabetic compound, an anti-hyperlipidemic compound, an antioxidant, an antithrombotic and vasodilator compound, a β -adrenergic antagonist, a calcium channel blocker, a digitalis, a diuretic, an endothelin antagonist, a hydralazine compound, a H_2 receptor antagonist, a neutral endopeptidase inhibitor, a nonsteroidal antiinflammatory compound, a
25 phosphodiesterase inhibitor, a potassium channel blocker, a platelet reducing agent, a proton pump inhibitor, a renin inhibitor, a selective cyclooxygenase-2 inhibitor, or a combination of two or more thereof.

30 15. The composition of claim 14, wherein the therapeutic agent is at least one compound selected from the group consisting of an aldosterone antagonist, an angiotensin II antagonist, an angiotensin-converting enzyme inhibitor, a β -adrenergic antagonist, a diuretic and a hydralazine compound.

16. The composition of claim 15, wherein the aldosterone antagonist is eplerenone or spironolactone; the angiotensin II antagonist is candesartan cilexetil, eprosartan mesylate, irbesartan, losartan potassium, medoxomil, telmisartan, trandolapril, trandolaprilat or valsartan; the angiotensin-converting enzyme inhibitor is
5 benazepril hydrochloride, captopril, enalapril maleate, fosinopril sodium, lisinopril, moexipril hydrochloride, quinapril hydrochloride; the β -adrenergic antagonist is bisoprolol fumarate, carvedilol, metoprolol tartrate, propranolol hydrochloride or timolol maleate; the diuretic is amiloride hydrochloride, chlorthalidone, hydrochlorothiazide or triamterene; and the hydralazine compound is hydralazine
10 hydrochloride.

17. The composition of claim 13, wherein the nitric oxide donor compound is selected from the group consisting of a S-nitrosothiol, a nitrite, a nitrate, a S-nitrothiol, a sydnonimine, a NONOate, a N-nitrosoamine, a N-hydroxyl nitrosamine, a nitrosimine, a diazetine dioxide, an oxatriazole 5-imine, an oxime, a hydroxylamine, a
15 N-hydroxyguanidine, a hydroxyurea or a furoxan.

18. The method of claim 7, 10 or 12, further comprising administering (i) at least one therapeutic agent; (ii) at least one nitric oxide donor compound; or (iii) at least one therapeutic agent and at least one nitric oxide donor compound.

19 The method of claim 18, wherein the therapeutic agent is an aldosterone
20 antagonist, an α -adrenergic receptor antagonist, an angiotensin II antagonist, an angiotensin-converting enzyme inhibitor, an antidiabetic compound, an anti-hyperlipidemic compound, an antioxidant, an antithrombotic and vasodilator compound, a β -adrenergic antagonist, a calcium channel blocker, a digitalis, a diuretic, an endothelin antagonist, a hydralazine compound, a H_2 receptor antagonist, a neutral
25 endopeptidase inhibitor, a nonsteroidal antiinflammatory compound, a phosphodiesterase inhibitor, a potassium channel blocker, a platelet reducing agent, a proton pump inhibitor, a renin inhibitor, a selective cyclooxygenase-2 inhibitor, or a combination of two or more thereof.

20 The method of claim 19, wherein the therapeutic agent is at least one
30 compound selected from the group consisting of an aldosterone antagonist, an angiotensin II antagonist, an angiotensin-converting enzyme inhibitor, a β -adrenergic

antagonist, a diuretic and a hydralazine compound.

21 The method of claim 20, wherein the aldosterone antagonist is eplerenone or spironolactone; the angiotensin II antagonist is candesartan cilexetil, eprosartan mesylate, irbesartan, losartan potassium, medoxomil, telmisartan,
5 trandolapril, trandolaprilat or valsartan; the angiotensin-converting enzyme inhibitor is benazepril hydrochloride, captopril, enalapril maleate, fosinopril sodium, lisinopril, moexipril hydrochloride or quinapril hydrochloride; the β -adrenergic antagonist is bisoprolol fumarate, carvedilol, metoprolol tartrate, propranolol hydrochloride or timolol maleate; the diuretic is amiloride hydrochloride, chlorthalidone,
10 hydrochlorothiazide or triamterene; and the hydralazine compound is hydralazine hydrochloride.

22. The method of claim 18, wherein the nitric oxide donor compound is selected from the group consisting of a S-nitrosothiol, a nitrite, a nitrate, a S-nitrothiol, a sydnonimine, a NONOate, a N-nitrosoamine, a N-hydroxyl nitrosamine, a
15 nitrosimine, a diazetine dioxide, an oxatriazole 5-imine, an oxime, a hydroxylamine, a N-hydroxyguanidine, a hydroxyurea or a furoxan.

23. A kit comprising at least one compound of claim 1.

24. The kit of claim 23, further comprising further comprising (i) at least one therapeutic agent; (ii) at least one nitric oxide donor compound; or (iii) at least one
20 therapeutic agent and at least one nitric oxide donor compound.

25. The kit of claim 24, wherein the (i) at least one therapeutic agent; (ii) at least one nitric oxide donor compound; or (iii) at least one therapeutic agent and at least one nitric oxide donor compound are in the form of separate components in the kit.